Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia
Background Pseudomonas aeruginosa pneumonia is commonly treated with systemic antibiotics to ensure adequate treatment of multidrug resistant (MDR) bacteria. However, intravenous (IV) antibiotics often achieve suboptimal pulmonary concentrations. We therefore aimed to evaluate the effect of inhaled amikacin (AMK) plus IV meropenem (MEM) on bactericidal efficacy in a swine model of monolateral MDR P. aeruginosa pneumonia. Methods We ventilated 18 pigs with monolateral MDR P. aeruginosa pneumonia for up to 102 h. At 24 h after the bacterial challenge, the animals were randomized to receive 72 h of treatment with either inhaled saline (control), IV MEM only, or IV-MEM plus inhaled AMK (MEM + AMK). We dosed IV MEM at 25 mg/kg every 8 h and inhaled AMK at 400 mg every 12 h. The primary outcomes were the P. aeruginosa burden and histopathological injury in lung tissue. Secondary outcomes included the P. aeruginosa burden in tracheal secretions and bronchoalveolar lavage fluid, the development of antibiotic resistance, the antibiotic distribution, and the levels of inflammatory markers. Results The median (25–75th percentile) P. aeruginosa lung burden for animals in the control, MEM only, and MEM + AMK groups was 2.91 (1.75–5.69), 0.72 (0.12–3.35), and 0.90 (0–4.55) $ log_{10} $ CFU/g (p = 0.009). Inhaled therapy had no effect on preventing dissemination compared to systemic monotherapy, but it did have significantly higher bactericidal efficacy in tracheal secretions only. Remarkably, the minimum inhibitory concentration of MEM increased to > 32 mg/L after 72-h exposure to monotherapy in 83% of animals, while the addition of AMK prevented this increase (p = 0.037). Adjunctive therapy also slightly affected interleukin-1β downregulation. Despite finding high AMK concentrations in pulmonary samples, we found no paired differences in the epithelial lining fluid concentration between infected and non-infected lungs. Finally, a non-significant trend was observed for higher amikacin penetration in low-affected lung areas. Conclusions In a swine model of monolateral MDR P. aeruginosa pneumonia, resistant to the inhaled AMK and susceptible to the IV antibiotic, the use of AMK as an adjuvant treatment offered no benefits for either the colonization of pulmonary tissue or the prevention of pathogen dissemination. However, inhaled AMK improved bacterial eradication in the proximal airways and hindered antibiotic resistance..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Critical care - 27(2023), 1 vom: 14. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Motos, Ana [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Animal model |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1186/s13054-023-04331-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR051455269 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR051455269 | ||
| 003 | DE-627 | ||
| 005 | 20230510063054.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230508s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13054-023-04331-x |2 doi | |
| 035 | |a (DE-627)SPR051455269 | ||
| 035 | |a (SPR)s13054-023-04331-x-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Motos, Ana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inhaled amikacin for pneumonia treatment and dissemination prevention: an experimental model of severe monolateral Pseudomonas aeruginosa pneumonia |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Background Pseudomonas aeruginosa pneumonia is commonly treated with systemic antibiotics to ensure adequate treatment of multidrug resistant (MDR) bacteria. However, intravenous (IV) antibiotics often achieve suboptimal pulmonary concentrations. We therefore aimed to evaluate the effect of inhaled amikacin (AMK) plus IV meropenem (MEM) on bactericidal efficacy in a swine model of monolateral MDR P. aeruginosa pneumonia. Methods We ventilated 18 pigs with monolateral MDR P. aeruginosa pneumonia for up to 102 h. At 24 h after the bacterial challenge, the animals were randomized to receive 72 h of treatment with either inhaled saline (control), IV MEM only, or IV-MEM plus inhaled AMK (MEM + AMK). We dosed IV MEM at 25 mg/kg every 8 h and inhaled AMK at 400 mg every 12 h. The primary outcomes were the P. aeruginosa burden and histopathological injury in lung tissue. Secondary outcomes included the P. aeruginosa burden in tracheal secretions and bronchoalveolar lavage fluid, the development of antibiotic resistance, the antibiotic distribution, and the levels of inflammatory markers. Results The median (25–75th percentile) P. aeruginosa lung burden for animals in the control, MEM only, and MEM + AMK groups was 2.91 (1.75–5.69), 0.72 (0.12–3.35), and 0.90 (0–4.55) $ log_{10} $ CFU/g (p = 0.009). Inhaled therapy had no effect on preventing dissemination compared to systemic monotherapy, but it did have significantly higher bactericidal efficacy in tracheal secretions only. Remarkably, the minimum inhibitory concentration of MEM increased to > 32 mg/L after 72-h exposure to monotherapy in 83% of animals, while the addition of AMK prevented this increase (p = 0.037). Adjunctive therapy also slightly affected interleukin-1β downregulation. Despite finding high AMK concentrations in pulmonary samples, we found no paired differences in the epithelial lining fluid concentration between infected and non-infected lungs. Finally, a non-significant trend was observed for higher amikacin penetration in low-affected lung areas. Conclusions In a swine model of monolateral MDR P. aeruginosa pneumonia, resistant to the inhaled AMK and susceptible to the IV antibiotic, the use of AMK as an adjuvant treatment offered no benefits for either the colonization of pulmonary tissue or the prevention of pathogen dissemination. However, inhaled AMK improved bacterial eradication in the proximal airways and hindered antibiotic resistance. | ||
| 650 | 4 | |a Inhaled amikacin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Severe pneumonia |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Animal model |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Multidrug resistance |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Monolateral pneumonia |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Yang, Hua |4 aut | |
| 700 | 1 | |a Li Bassi, Gianluigi |4 aut | |
| 700 | 1 | |a Yang, Minlan |4 aut | |
| 700 | 1 | |a Meli, Andrea |4 aut | |
| 700 | 1 | |a Battaglini, Denise |4 aut | |
| 700 | 1 | |a Cabrera, Roberto |4 aut | |
| 700 | 1 | |a Bobi, Joaquim |4 aut | |
| 700 | 1 | |a Pagliara, Francesco |4 aut | |
| 700 | 1 | |a Frigola, Gerard |4 aut | |
| 700 | 1 | |a Camprubí-Rimblas, Marta |4 aut | |
| 700 | 1 | |a Fernández-Barat, Laia |4 aut | |
| 700 | 1 | |a Rigol, Montserrat |4 aut | |
| 700 | 1 | |a Ferrer-Segarra, Antoni |4 aut | |
| 700 | 1 | |a Kiarostami, Kasra |4 aut | |
| 700 | 1 | |a Martinez, Daniel |4 aut | |
| 700 | 1 | |a Nicolau, David P. |4 aut | |
| 700 | 1 | |a Artigas, Antonio |4 aut | |
| 700 | 1 | |a Pelosi, Paolo |4 aut | |
| 700 | 1 | |a Vila, Jordi |4 aut | |
| 700 | 1 | |a Torres, Antoni |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Critical care |d London : BioMed Central, 1997 |g 27(2023), 1 vom: 14. Feb. |w (DE-627)SPR029726166 |w (DE-600)2051256-9 |x 1364-8535 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2023 |g number:1 |g day:14 |g month:02 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13054-023-04331-x |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2023 |e 1 |b 14 |c 02 | ||